Table 2 Descriptive statistics
From: Side effects during chemotherapy predict tumour response in advanced colorectal cancer
Response to Treatment | |||
|---|---|---|---|
CR+PR+SD vs | PD | ||
(n =245) | (n =58) | Total ( n =303) | |
Gender | |||
Female | 88 (77.9%) | 25 (22.1%) | 113 |
Male | 157 (82.6%) | 33 (17.4%) | 190 |
Age | |||
Up to 65 years | 127 (79.4%) | 33 (20.6%) | 160 |
Older than 65 years | 118 (82.5%) | 25 (17.5%) | 143 |
Mean (±s.d.) | 63.12 (±9.70) | 62.05 (±9.93) | 62.92 (±9.74) |
Min–max | 37–79 | 38–77 | 37–79 |
Number of side effects | |||
Median (min–max) | 6 (0–12) | 4 (0–13) | 6 (0–13) |
Number of side effects WHO-grade < 2 (n=284) | |||
Median (min–max) | 3 (0–10) | 2 (0–7) | 3 (0–10) |
Number of side effects WHO-grade⩾2 (n=45) | |||
Median (min–max) | 2 (0–9) | 1 (0–7) | 2 (0–9) |
Number of haematological side effects (n=252) | |||
Median (min–max) | 3 (0–4) | 1 (0–4) | 2 (0–4) |
Number of non-haematological side effects (n=289) | |||
Median (min–max) | 4 (0–9) | 2 (0–9) | 3 (0–9) |
Number of tumour sites | |||
Median (min–max) | 2 (1–5) | 2 (1–5) | 2 (1–5) |
Chemotherapy regimen | |||
Capecitabine plus oxaliplatin | 80 (87.0%) | 12 (13.0%) | 92 |
Raltitrexed plus oxaliplatin | 82 (91.1%) | 8 (8.9%) | 90 |
Irinotecan plus oxaliplatin | 53 (82.8%) | 11 (17.2%) | 64 |
Raltitrexed | 30 (52.6%) | 27 (47.4%) | 57 |
